Sitagliptin (Januvia™) is a new oral agent approved by the US FDA to treat Type 2 diabetes. This is the first approved agent in a new class of antihyperglycemics, dipeptidyl peptidase (DPP)-4 ...

In 2025, the deductible cannot exceed $590. Januvia (sitagliptin) is a prescription-only medication for type 2 diabetes. It can work alongside diet and exercise to help lower blood sugar (glucose ...

The latest verdict – in a federal appeals court – has upheld the validity of a key patent on sitagliptin, the active ingredient in Januvia, as well as metformin combinations Janumet and ...

as a fixed-dose combination of ertuglifloziun and Merck’s DPP-4 inhibitor Januvia (sitagliptin), and as a fixed-dose combination with metformin. European regulators are also reviewing ...

Januvia (sitagliptin) Onglyza (saxagliptin) Tradjenta (lingliptin) Nesina (alogliptin) Glucagon-Like Peptide-1 Agonists (GLP-1s) Glucagon-like peptide-1 agonists (GLP-1s) can increase the release ...

Researchers from the US have shown that combination therapy with sitagliptin and metformin results in a substantial and additive glycemic improvement in patients with type 2 diabetes. Sitagliptin ...

Expert Rev Endocrinol Metab. 2008;3(6):691-697. Elimination of sitagliptin occurs primarily via renal excretion (79%) and involves active tubular secretion. Sitagliptin is a substrate for human ...